Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Using MRD as an endpoint in clinical trials

Hervé Avet-Loiseau • 14 Sep 2019
IMW 2019
Multiple Myeloma

Hervé Avet-Loiseau, MD, PhD, Cancer Research Center of Toulouse, Toulouse, France, outlines the potential benefits of using (measurable residual disease) MRD as an
an endpoint in myeloma treatment at the International Myeloma Workshop (IMW) 2019, Boston, MA.

More from Hervé Avet-Loiseau

Comparing MRD analysis methods
2:11
Comparing MRD analysis methods
Hervé Avet-Loiseau • 14 Sep 2019
Working towards a cure for multiple myeloma
14:15
Working towards a cure for multiple myeloma
Hervé Avet-Loiseau • 27 Jan 2017
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
11:23
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
Hervé Avet-Loiseau • 27 Jan 2017
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
3:22
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Hervé Avet-Loiseau • 30 Apr 2016

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Hervé Avet-Loiseau • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Hervé Avet-Loiseau • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Hervé Avet-Loiseau • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Hervé Avet-Loiseau • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals